MedTrace Logo

The Cooling And Surviving Septic Shock Study (CASS)

NCT01455116 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 433

Last updated 2016-11-22

No results posted yet for this study

Summary

Septic shock is in critically ill patients is a condition associated with a high rate of organ failure and hereto attributable mortality \~45-55% Hypothesis: Mild Induced Hypothermia reduces the mortality of critically ill patients with septic shock by reducing organ metabolism, counteracting on microcirculatory thrombosis, genetically downregulating tissue apoptosis and by reducing bacterial growth rate and toxin production.

Conditions

  • Septic Shock

Interventions

PROCEDURE

Mild Induced Hypothermia

Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit

Sponsors & Collaborators

  • TRYG Foundation

    collaborator OTHER

  • Lundbeck Foundation

    collaborator OTHER

  • Danish Procalcitonin Study Group

    lead OTHER

Principal Investigators

  • Jens Ulrik S Jensen, MD, PhD · CHIP & PERSIMUNE, Rigshospitalet, University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United States
  • Denmark
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01455116 on ClinicalTrials.gov